• InforMedix Holdings (Rockville, Maryland) said that its Med-eMonitor System, designed to improve patient medication compliance and protocol adherence in disease management and clinical drug trials programs, improved mean medication adherence rates to more than 92% compared to a baseline medication adherence rate of 40% in a medication management program involving Type 2 diabetes patients at St. Vincent Healthcare (Billings, Montana). The Med-eMonitor System also reduced Hemoglobin A1c (HbA1c) levels by an average of 18.5% in a three-month period.

• Media Cybernetics (Silver Spring, Maryland), which develops image informatics solutions, reported the release of InVivo Analyzer Suite 3.0 for live cell imaging. InVivo Analyzer Suite combines three powerful scientific software applications into a complete live cell imaging solution: the fast acquisition tools of InVivo; the advanced analytical capabilities of Image-Pro Analyzer; and the sophisticated 3-D rendering features of 3D Constructor. InVivo Analyzer Suite 3.0 includes a FRET Experiment Wizard that guides users through the complex process of evaluating the relationship between two fluorescent molecules. New ratio imaging features include an intensity calibration interface for ratio imaging acquisition and the ability to conduct live ratio measurement and display when using an optical splitter. Users can apply variable rate time-lapse settings when acquiring images. InVivo Analyzer Suite also supports automatic calculation of Nyquist sampling for 3-D acquisition. InVivo Analyzer Suite 3.0 has added hardware support for the latest cameras, wavelength selection, biological chambers and other devices critical for live cell imaging. It also offers multi-camera support, which allows up to four cameras to be used at one time.

• Ophthonix (San Diego), a vision care company developing a high definition vision technology, said it has secured a ninth patent for its wavefront technology. The patent protects the method of manufacturing a lens that provides a variation of refractive indices that compensate for low- and high-order aberrations. The patented Ophthonix process involves sandwiching an epoxy between two plates, which is cured by radiation in a pre-programmed method, enabling the incorporation of both low- and high-order correction for each individual eye. By using the two lenses and epoxy, Ophthonix is able to provide customized lenses by appropriately programming the curing of the epoxy.